Q-linea AB (QLINEA) AI Stock Analysis

• Market Cap: kr300.27M
• Dividend Yield: N/A
• Average Volume (3M): 22.77M
• Price to Earnings (P/E): ―
• Beta (1Y): 3.67
• Revenue Growth: -22.50%
• EPS Growth: 76.74%
• Country: SE
• Employees: 97
• Sector: Healthcare
• Sector Strength: 58
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.02
• Shares Outstanding: 6,430,039,600
• 10 Day Avg. Volume: 20,431,349
• 30 Day Avg. Volume: 22,772,697
• PEG Ratio: -0.01
• Price to Book (P/B): 0.71
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 43 Neutral
• Price Target: kr0.00 ▼(-100.00%Downside)

Q-linea AB's overall stock score is primarily impacted by its weak financial performance, with persistent unprofitability and negative cash flows posing significant risks to its sustainability. The technical analysis provides a neutral outlook, while the valuation remains unattractive due to negative earnings and the lack of dividends. These factors collectively result in a low overall score, reflecting the company's financial instability and market uncertainty.

Q-linea AB Business Overview & Revenue Model

Company Description

Q-linea AB (QLINEA) is a Swedish biotechnology company specializing in the development of advanced diagnostic systems for healthcare providers. The company focuses primarily on creating innovative solutions for the rapid diagnosis of infectious diseases. Q-linea's core product, the ASTar system, is designed to offer fast and precise antimicrobial susceptibility testing, helping medical professionals make informed treatment decisions more efficiently.

How the Company Makes Money

Q-linea makes money by selling its diagnostic systems, particularly the ASTar system, to hospitals and clinical laboratories. Revenue is generated through the direct sale of these systems, as well as ongoing sales of consumables and reagents needed for their operation. The company may also engage in strategic partnerships or collaborations with other healthcare organizations and institutions to expand its market reach and improve its product offerings. Additionally, Q-linea might secure revenue through service contracts and maintenance agreements with its clients, ensuring the optimal functioning of its diagnostic systems.

Q-linea AB Financial Statement Overview

Summary

Q-linea AB faces significant financial challenges. The income statement highlights unprofitability with declining revenue and negative margins. The balance sheet reflects financial instability with high debt levels and negative equity. Cash flow analysis shows poor management and reliance on external funding, exacerbating sustainability concerns.

Income Statement

The income statement reveals significant challenges for Q-linea AB, with negative gross profit, net income, and EBIT margins, indicating unprofitability. There is a notable decline in revenue over recent periods, with a TTM revenue lower than the previous year. The consistent negative EBIT and EBITDA margins further highlight operational inefficiencies and the inability to cover operating expenses with revenue.

Balance Sheet

The balance sheet shows a concerning financial structure. The company has a high level of debt relative to equity, as seen in the negative stockholders' equity in 2024. The equity ratio improved in the TTM period due to increased stockholders' equity, but the company still exhibits financial instability, as evidenced by a history of negative net equity and increasing liabilities.

Cash Flow

Q-linea AB’s cash flow statement shows significant negative free cash flow and operating cash flow, indicating poor cash management and operational challenges. Despite positive financing cash flow, driven by external funding, the operating cash flow to net income ratio is unfavorable, highlighting cash flow issues relative to reported income. The lack of positive free cash flow growth exacerbates concerns about the company’s sustainability.

Breakdown
TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
4.57M	2.36M	4.44M	12.79M	9.34M	243.00K
	Gross Profit
-72.66M	-11.11M	995.00K	-21.38M	-25.03M	-32.02M
	EBIT
-202.36M	-213.64M	-230.59M	-262.25M	-233.55M	-221.54M
	EBITDA
-184.76M	-195.40M	-210.99M	-252.69M	-218.48M	-211.02M
	Net Income Common Stockholders
-206.17M	-216.87M	-229.37M	-275.77M	-233.18M	-220.19M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
68.03M	25.66M	81.89M	72.62M	166.03M	306.89M
	Total Assets
193.90M	147.99M	231.98M	207.39M	466.63M	412.23M
	Total Debt
51.09M	151.21M	20.56M	20.93M	79.00K	331.00K
	Net Debt
-16.94M	125.54M	-61.33M	-51.69M	-15.01M	-9.81M
	Total Liabilities
73.89M	175.45M	42.34M	45.76M	35.84M	32.03M
	Stockholders Equity
120.01M	-27.46M	189.64M	161.63M	430.79M	380.20M
Cash Flow		Free Cash Flow
-187.36M	-187.49M	-236.86M	-268.11M	-267.02M	-250.53M
	Operating Cash Flow
-184.62M	-182.50M	-228.52M	-250.86M	-255.05M	-237.31M
	Investing Cash Flow
-1.79M	-5.04M	-7.77M	315.25M	-23.82M	-32.30M
	Financing Cash Flow
225.27M	131.27M	245.41M	-6.60M	283.81M	253.78M

Q-linea AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.05
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:QLINEA, the sentiment is Negative. The current price of 0.05 is above the 20-day moving average (MA) of 0.05, above the 50-day MA of 0.04, and below the 200-day MA of 0.21, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 47.94 is Neutral, neither overbought nor oversold. The STOCH value of 28.79 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:QLINEA.

Q-linea AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	54 Neutral	$5.41B	3.27	-45.10%	3.29%	16.81%	0.02%
ACARIX	46 Neutral	€257.96M	―	-88.97%	―	-0.61%	54.19%
QLINEA	43 Neutral	kr300.27M	―	-159.24%	―	-22.50%	76.74%
SCIB	43 Neutral	kr133.63M	―	-209.61%	―	27.78%	43.32%
SPEC	41 Neutral	kr198.30M	―	-20.45%	―	―	-10.85%
LXB	37 Underperform	kr99.92M	―	-51.52%	―	955.20%	47.31%
CLS.B	34 Underperform	kr55.96M	―	-79.12%	―	127.04%	92.31%

Q-linea AB Corporate Events

Q-linea AB Expands Share Capital with New Issuance

Q-linea AB has announced an increase in its number of shares and votes following the exercise of TO1 warrants, resulting in a total of 6,430,039,725 shares. This expansion reflects the company’s growth and could enhance its market presence, impacting stakeholders by potentially increasing shareholder value.

Q-linea AB Proposes Reverse Share Split and Capital Reduction

Q-linea AB’s board of directors has proposed a reverse share split and a reduction in share capital to be resolved at the annual general meeting. The reverse share split aims to consolidate 1,000 shares into 1 to stabilize the share price and adjust the number of shares, while the capital reduction seeks to align the company’s capital structure with its operational needs without affecting shareholder value.

Q-linea AB Announces 2025 Annual General Meeting and Key Resolutions

Q-linea AB has announced its annual general meeting scheduled for June 26, 2025, in Uppsala, Sweden. Key agenda items include the election of board members, approval of financial statements, and decisions on share capital adjustments. The nomination committee proposes no dividend for 2024, a slight increase in board remuneration, and resolutions on share capital reduction and extension of a loan from a related party. These decisions are aimed at strengthening the company’s financial position and governance structure.

Q-linea AB Successfully Exercises Series TO1 Warrants

Q-linea AB announced the successful exercise of 91.5% of its series TO1 warrants, resulting in the subscription of nearly 2 billion new shares at SEK 0.03 each, raising approximately 59.5 MSEK before transaction costs. This exercise increases the company’s share capital significantly and results in a dilution effect of about 30.8%, impacting the company’s financial structure and market positioning.

Q-linea AB Concludes Trading in Warrants Series TO 1

Q-linea AB announced that 15 May 2025 marks the last day for trading in its warrants series TO 1, with the subscription of shares ongoing until 19 May 2025. The company has received significant subscription intentions from major shareholders and its board, potentially raising SEK 65.0 million before issue costs if all warrants are exercised, which would result in a 32.7 percent dilution of shares.

Q-linea AB Announces Board Member Nominations for 2025

Q-linea AB’s nomination committee has proposed the re-election and election of board members, including Johan Bygge as chairman and Sebastian Backlund as a new member, at the upcoming annual general meeting. These appointments are expected to strengthen Q-linea’s strategic direction, leveraging Bygge’s global business experience and Backlund’s financial expertise, as the company continues its commercialization phase.